Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

226.38 -5.20 (-2.25%)
Streaming Delayed Price Updated: 2:45 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
The U.S. 
Via Benzinga
7 Low-Volatility Stocks to Buy if You’re a Concerned Investor
With market and economic conditions worrying many investors, it may be time to consider the virtues of low-volatility stocks. 
Via InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ: 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today
Via Benzinga
Is Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy. 
Via The Motley Fool
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio
Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Biotech Sector: On The Verge Of Triumph Or Turmoil?
In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise. 
Via Talk Markets
An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”: 
Via Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder. 
Via Investor's Business Daily
Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
Benzinga 
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be 
Via Benzinga
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing... 
Via Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors. 
Via The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners. 
Via InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a  
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
Better Buy: Biogen vs. Eli Lilly
This battle of biotech giants has a clear winner. 
Via The Motley Fool
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™... 
Via Benzinga
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
The company is now focusing on its launch in postpartum depression. 
Via Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.